Optos sees profits rise as it expands

Optos's full-year results beat consensus estimates, driven by increased sales geographically and helped by the roll-out of its latest Daytona device.

Optos's full-year results beat consensus estimates, driven by increased sales geographically and helped by the roll-out of its latest Daytona device.

For the full year ended September 30th it delivered pre-tax profits of $23.4m (2011: $22m) on revenues of $193.2m (2011: $143.3m) - excluding an additional $3.2m income from the extension of previously-recognised finance leases. This was ahead of consensus estimates of $22.7m in pre-tax profits and $188m in turnover.

Helped by a growing direct and indirect sales force its two geographic segments both delivered double digit increases, with North American sales growing 26% to $147.8m and International sales growing 85% to $48.6m.

For the next financial year, Chief Executive Officer, Roy Davies stressed: "...our priority will be to execute on Daytona and continue our expansion into the ophthalmology market with the 200Tx device."

Still, progress has been made. There was $21m in revenues from Daytona, its next generation desktop retinal imaging device, with 329 devices installed this year. However, the timing of manufacturing scale up of Daytona contributed to a fall in gross margin from 64% to 57%. The year also saw accelerated growth in ophthalmology, with over 320 200Tx devices installed globally.

Given that its business model has changed from a pay-per-patient rental model to that where customers now acquire their devices outright or through finance leases it is hardly surprising that this is reflected in the sales mix. Outright sales of devices were $64.2m (2011: $37.6m) and new sales under finance leases of were $64.1m (2011:$37.6m). Revenues from operating leases fell to $52.5m (2011: $81.2m). With more customers entering into service contracts, recurring revenues from service and warranty grew to $15.6m (2011: $4.7m).

The results certainly pleased Panmure Gordon analyst Savvas Neophytou, who has reiterated his 'buy' recommendation and 320p price target.

CM

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022